NCT00407888View on ClinicalTrials.gov

Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

July 31, 2012

Conditions
Estrogen Receptor-positive Breast CancerHER2-positive Breast CancerStage IA Breast CancerStage IB Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
DRUG

doxorubicin hydrochloride

Given IV

DRUG

cyclophosphamide

Given orally

BIOLOGICAL

filgrastim

Given SC

DRUG

paclitaxel albumin-stabilized nanoparticle formulation

Given IV

BIOLOGICAL

trastuzumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

quality-of-life assessment

Ancillary studies

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT00407888 - Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery | Biotech Hunter | Biotech Hunter